Theron Odlaug

Dr. Theron (Ted) Odlaug brings over 40 years of experience with significant leadership roles in the pharmaceutical industry.
Ted is an advisor to Signet and has worked with several Signet portfolio companies over the last 14 plus years.
Ted is currently a Board Member of Signet portfolio companies Ascendia Pharmaceuticals Inc. and Pharma Nobis, LLC.
He is also President of the Board of the Dravet Syndrome Foundation.
He was a Board Member of CoreRx Inc. until the 2021 sale to NovaQuest.
Prior he was Executive Chairman of Impopharma Inc. and CEO of leon-nanodrugs GmbH, and a member of its Supervisory Board.
He was the Executive Chairman of Cedarburg Pharmaceuticals until the company was sold to Albany Molecular Research Inc. in 2014.
From 2011 Ted was the Executive Chairman and CEO of Planet Biopharmaceuticals until the company was sold to Ares Life Sciences in 2014.
From 2008 until 2011, he was President and CEO of CyDex Pharmaceuticals, Inc. at which time the company was sold to Ligand Pharmaceuticals, Inc. Prior to that, he was Executive Vice President and a member of the senior management committee at Fujisawa Healthcare Inc. until its merger with Yamanouchi in 2005, which resulted in the formation of Astellas Pharma.
He left Astellas in 2006 after successfully supporting the U.S.
post-merger integration process.
Earlier in his career he had senior positions at Bayer AG and Baxter.
Ted holds Bachelor's and Master's degrees from the University of Missouri at Kansas City and a Ph.D.
in Public Health from the University of Minnesota.